• No results found

Image Guided Intensity Modulated Radiotherapy in Head and Neck Cancer.

N/A
N/A
Protected

Academic year: 2021

Share "Image Guided Intensity Modulated Radiotherapy in Head and Neck Cancer."

Copied!
241
0
0

Loading.... (view fulltext now)

Full text

Figure

Figure  1.1.  Dose-painting w ith  IM R T as proposed by Ling et al  [2].
Figure  2.3.  Filling NEMA  lEC  Body Phantom w ith   solutions  of FDG to  obtain  required SBRs.
Table  2.2.  Summary  of increasing  quantities  of FDG  added  to  background  (BG) in phantom  to create decreasing SBR ranging from  9.85, down to 1.52.
Figure 2.5. Line of best fit showing relationship between SBR and threshold  required to isocontour spheres of 6 different volumes.
+7

References

Related documents

Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography

Tomotherapy-based IGRT may reduce the aspiration rate for non-laryngeal and non-hypopharyngeal head and neck cancer patients because of the decreased pharyngeal muscle dose.

27 consecutive patients were treated with increased dose intensity-modulated radiation therapy as part of defini- tive treatment of esophageal cancer at the German Cancer

This thesis describes the steps we have taken to arrive at a highly focused, image-guided radiation therapy (IGRT) technique for single vocal cord irradiation for early glottic

CRT: Chemoradiation; CRUK: Cancer Research UK; CTV: Clinical target volume; DARS: Dysphagia/aspiration at risk structures; DIGEST: Dynamic Imaging Grade of Swallowing Toxicity;

Intensity-modulated radiotherapy (IMRT) of whole pelvis for prostate cancer patients [7-13] treats the gross disease in the prostate gland as well as suspected in- volvement of

The reason for this is that each institute uses different optimization strategies and sets of objectives, and has dif- ferent preferences for sparing OARs while identical patient

[20] reported the acute toxicity and long- term outcome of 15 elderly esophageal cancer patients (>70) with multiple co-morbidities who were treated with concurrent chemoradiation